Page URL: https://www.bionews.org.uk/page_136013

Breast cancer drug works in half the time

21 May 2018
Appeared in BioNews 950

A new study indicates that an important drug used to treat breast cancer is just as effective when the course of treatment is shortened by half.

Herceptin, also known as trastuzumab, is used to treat human epidermal growth factor receptor 2 (HER2) positive breast cancer. This particularly aggressive form of breast cancer expresses a high level of HER2 protein, which promotes the division and growth of cells.

The PERSEPHONE study, carried out by researchers at the University of Cambridge, found that Herceptin treatment in patients with early-stage breast cancer is just as effective when taken for six months as when taken for a full year. 

Professor Helena Earl, chief investigator of the study, said: 'We are confident that this will mark the first steps towards a reduction in treatment duration for many women with HER2-positive breast cancer.'

Determining the optimum treatment duration is important because of Herceptin's serious side effects. Herceptin has high toxicity within the body, which worsens with increased use and can result in permanent damage, such as congestive heart failure or stroke.

The phase III randomised trial enrolled 4089 women aged between 23 and 82 years with HER2 positive breast cancer and followed them for a median of 4.9 years after treatment. The results demonstrated that there was no significant difference in disease-free survival at four years: 89 percent in both groups. 

Adverse effects were significantly different between the groups, however. Only 4 percent of patients in the six months treatment group forced to stop taking the drug due to cardiotoxicity, compared with 8 percent in the 12 months group.

'I have personally seen congestive heart failure caused by Herceptin,' Dr Otis Brawley, chief medical and scientific officer of the American Cancer Society, told The New York Times. 'The longer you give it, the likelier they are to get it. So it's a wonderful thing if you can give it for a shorter time.'

The data is currently unpublished but it is due to be presented for the first time at the American Society of Clinical Oncology annual meeting in June 2018.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE
13 August 2018 - by Jen Willows 
A study has identified five genes that are associated with an aggressive form of breast cancer...
16 July 2018 - by Charlott Repschlager 
Assisted reproduction techniques such as IVF do not increase a woman's risk of developing womb or breast cancer, a new study has found...
11 June 2018 - by Grace O'Regan 
Chemotherapy is not necessary to treat the most common type of breast cancer in 69 percent of cases, a new study has shown...
8 May 2018 - by Dr James Heather 
Genetic testing could reveal a subset of patients with aggressive breast cancer who would benefit from a non-standard treatment, a clinical trial has found...
12 June 2017 - by Dr Loredana Guglielmi 
A drug treatment for ovarian cancer has shown success against inherited breast cancer...
22 August 2016 - by Ebtehal Moussa 
Researchers in the UK have discovered two key genes capable of predicting 10-year disease-specific survival outcomes in breast cancer patients...
19 January 2015 - by Kirsty Oswald 
UK researchers have identified a gene that is active in a difficult-to-treat form of breast cancer, raising the possibility of developing targeted treatments.
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.